Menu
Novartis and BMS filed an emergency motion with the federal appeals court in Washington, D.C. to appeal a recent ruling on drugmaker 340B rebates.

In Emergency Motion, Novartis and BMS Urge Appellate Court to Fast-Track Their Appeals of 340B Rebate Ruling

William Newton, Associate Editor/Senior Writer 340B Report Views
Novartis and Bristol Myers Squibb (BMS) are asking a federal appeals court to expedite their challenge to a recent ruling [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Premier Asks Court to Reject HRSA’s Defense of 340B Hospital Drug Purchasing Restrictions Policy, Requests Oral Arguments

Drug-Industry Funded Study Finds Utilization Drives 340B Program Growth, Not Rising Drug Prices

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Site Footer Live